Description
We have just lived through a brand-new pandemic. This has highlighted the risks of new infections from animals, and the difficulty of eradication. On the otherhand, development of vaccines and drugs against SARS CoV-2 in record time promise to help mitigate its worst effects. ÌýOnly two viruses have already been eradicated from the globe: smallpox and rinderpest. The WHO has set priorities for the next targets, which include poliovirus and measles.
In this module, we will explore the biological, human demographic and political characteristics of particular viruses that might be considered for eradication in the future. In doing so, we will consider the cost effectiveness of eradication as a strategy and we will review the current progress towards controlling these virus infections in the community through immunisation.
The development and deployment of vaccines requires expertise and support from a variety of specialist disciplines including virology, immunology, biotechnology, clinical trial design, government regulatory agencies, government decision-making bodies, public health organisations and major charities. External speakers with experience of several of these areas will teach on the module and share their perspectives and insights.
Learning objectives
- Have a sound knowledge and understanding of virus biology and epidemiology in the context of vaccine development and usage.
- Gain an appreciation of the multi-disciplinary approach necessary for vaccine evaluation and deployment.
- Understand the requirements for and challenge of vaccine-based control, elimination and eradication of viruses.
Module deliveries for 2024/25 academic year
Last updated
This module description was last updated on 19th August 2024.
Ìý